Journal article
Quantitative Imaging in Cancer Clinical Trials
Clinical cancer research, Vol.22(2), pp.284-290
01/15/2016
DOI: 10.1158/1078-0432.CCR-14-3336
PMCID: PMC4717912
PMID: 26773162
Abstract
As anticancer therapies designed to target specific molecular pathways have been developed, it has become critical to develop methods to assess the response induced by such agents. Although traditional, anatomic CT, and MRI examinations are useful in many settings, increasing evidence suggests that these methods cannot answer the fundamental biologic and physiologic questions essential for assessment and, eventually, prediction of treatment response in the clinical trial setting, especially in the critical period soon after treatment is initiated. To optimally apply advances in quantitative imaging methods to trials of targeted cancer therapy, new infrastructure improvements are needed that incorporate these emerging techniques into the settings where they are most likely to have impact. In this review, we first elucidate the needs for therapeutic response assessment in the era of molecularly targeted therapy and describe how quantitative imaging can most effectively provide scientifically and clinically relevant data. We then describe the tools and methods required to apply quantitative imaging and provide concrete examples of work making these advances practically available for routine application in clinical trials. We conclude by proposing strategies to surmount barriers to wider incorporation of these quantitative imaging methods into clinical trials and, eventually, clinical practice. Our goal is to encourage and guide the oncology community to deploy standardized quantitative imaging techniques in clinical trials to further personalize care for cancer patients and to provide a more efficient path for the development of improved targeted therapies.
Details
- Title: Subtitle
- Quantitative Imaging in Cancer Clinical Trials
- Creators
- Thomas E Yankeelov - Institute of Imaging Science, Departments of Radiology and Radiological Sciences, Biomedical Engineering, Physics, and Cancer Biology, Vanderbilt University, Nashville, Tennessee. thomas.yankeelov@utexas.eduDavid A Mankoff - Radiology/Nuclear Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PennsylvaniaLawrence H Schwartz - Department of Radiology, Columbia University, New York, New YorkFrank S Lieberman - Departments of Neurology, Neurosurgery and Medical Oncology, University of Pittsburgh, Pittsburgh, PennsylvaniaJohn M Buatti - Departments of Radiation Oncology, Otolaryngology, and Neurosurgery, University of Iowa, Iowa City, IowaJames M Mountz - Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh, Pittsburgh, PennsylvaniaBradley J Erickson - Department of Radiology, Mayo Clinic, Rochester, MinnesotaFiona M M Fennessy - Department of Radiology, Brigham and Women's Hospital, Boston, MassachusettsWei Huang - Advanced Imaging Research Center, Oregon Health and Science University, Portland, OregonJayashree Kalpathy-Cramer - Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MassachusettsRichard L Wahl - Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MarylandHannah M Linden - Department of Medicine, University of Washington, Seattle, WashingtonPaul E Kinahan - Department of Radiology, University of Washington, Seattle, WashingtonBinsheng Zhao - Department of Radiology, Columbia University, New York, New YorkNola M Hylton - Department of Radiology, University of California, San Francisco, San Francisco, CaliforniaRobert J Gillies - Department of Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa Bay, FloridaLaurence Clarke - Cancer Imaging Program, National Cancer Institute, Bethesda, MarylandRobert Nordstrom - Cancer Imaging Program, National Cancer Institute, Bethesda, MarylandDaniel L Rubin - Department of Radiology and Medicine, Stanford University, Palo Alto, California
- Resource Type
- Journal article
- Publication Details
- Clinical cancer research, Vol.22(2), pp.284-290
- DOI
- 10.1158/1078-0432.CCR-14-3336
- PMID
- 26773162
- PMCID
- PMC4717912
- NLM abbreviation
- Clin Cancer Res
- ISSN
- 1078-0432
- eISSN
- 1557-3265
- Publisher
- United States
- Grant note
- U01CA142565 / NCI NIH HHS U01 CA160045 / NCI NIH HHS U01 CA151235 / NCI NIH HHS U01CA190254 / NCI NIH HHS U01 CA140230 / NCI NIH HHS U01 CA142555 / NCI NIH HHS U01 CA154602 / NCI NIH HHS U01 CA143062 / NCI NIH HHS U01 CA140206 / NCI NIH HHS U01 CA148131 / NCI NIH HHS U01CA154601 / NCI NIH HHS U01CA151261 / NCI NIH HHS U01CA140207 / NCI NIH HHS U01 CA154601 / NCI NIH HHS U01CA140204 / NCI NIH HHS U01CA143062 / NCI NIH HHS U01CA140206 / NCI NIH HHS U01CA148131 / NCI NIH HHS U01CA151235 / NCI NIH HHS U01CA154602 / NCI NIH HHS U01 CA190214 / NCI NIH HHS U01 CA151261 / NCI NIH HHS P30 CA016520 / NCI NIH HHS U01 CA140204 / NCI NIH HHS P30 CA086862 / NCI NIH HHS U01CA140230 / NCI NIH HHS U01 CA190254 / NCI NIH HHS U01CA142555 / NCI NIH HHS U01 CA142565 / NCI NIH HHS U01 CA140207 / NCI NIH HHS U01CA160045 / NCI NIH HHS
- Language
- English
- Date published
- 01/15/2016
- Academic Unit
- Radiation Oncology; Neurosurgery; Otolaryngology
- Record Identifier
- 9984040264102771
Metrics
66 Record Views